ERCC1 Targeted Trial (ET)
A Multicentre, Randomised, Phase III Trial of Platinum-based Chemotherapy Versus Non-platinum Chemotherapy, After ERCC1 Stratification, in Patients With Advanced/Metastatic Non-small Cell Lung Cancer
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
TRIAL OBJECTIVES
Primary objective
The trial will have two main objectives:
- To detect an improvement in survival for ERCC1+ve patients treated with a non-platinum chemotherapy compared to platinum-based treatment.
- To establish non-inferiority or improvement in survival for ERCC1-ve patients treated with a platinum-based chemotherapy compared to non-platinum treatment.
Secondary objectives
- To examine progression-free survival, response rate and quality of life between the two treatment regimens, according to ERCC1 status.
- To investigate whether the treatment effect differs according to histology (squamous vs. nonsquamous);gender (males vs. females); performance status
- To undertake a cost-effectiveness analysis based on all patients, and according to ERCC1 status.
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
London、英国
- University College London Hospitals
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
INCLUSION CRITERIA
- Histological confirmation of non-squamous NSCLC
- Have a tissue biopsy available for sending to the central laboratory to determine ERCC1 status
- Presentation with stage IIIb (not amenable to curative treatment) or IV disease - staging scans must be no more than 28 days prior to registration. Patients with relapsed NSCLC must not have received prior chemotherapy or biological therapy (previous surgery or radical radiotherapy allowed)
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours
- Either sex, at least 18 years of age
- ECOG performance status 0-1
- Estimated life expectancy of at least 8 weeks
Adequate bone marrow function as evidenced by the following (assessed within 14 days of registration):
- Absolute neutrophil count (ANC) ≥1.5 × 109/L
- Platelet count ≥100 × 109/L
- Haemoglobin ≥9 g/dL
Adequate liver function as evidenced by the following (assessed within 14 days of registration):
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Aspartate transaminase (AST) ≤3 × ULN or ≤5 × ULN is acceptable with liver metastases
- Alanine transaminase (ALT) ≤3 × ULN
Adequate renal function as evidenced by the following (assessed within 14 days of registration):
- GFR > 60ml/min as measured by creatinine clearance through EDTA. Alternatively, the Cockcroft and Gault formula may be used to estimate GFR, but if < 60 ml/min then EDTA should be performed.
- Previous palliative radiotherapy to non-target metastatic lesions is allowed for pain relief prior to starting chemotherapy
- Patients with stable brain metastases will be allowed to enrol. Stable brain metastases being defined as no progression of brain metastases 28 days after treatment as documented by a CT scan/MRI of the brain. Patients with incidentally discovered asymptomatic brain metastases may be enrolled and treated with trial chemotherapy without prior brain irradiation if deemed feasible by the treating physician
- Signed informed consent form
- Use of effective contraception during, and for 6 months after trial treatment by patients of reproductive potential and partners of reproductive potential. Patients who receive aprepitant (anti-emetic) must be willing to use an alternative or back-up method to hormonal contraceptives as aprepitant may reduce their efficacy. Female patients with childbearing potential must have a negative serum pregnancy test prior to registration.
EXCLUSION CRITERIA
- Cytologically or clinically diagnosed NSCLC
- Evidence of significant medical condition or laboratory finding which, in the opinion of the treating physician or chief investigator, makes it undesirable for the patient to participate in the trial
- Presence of uncontrolled brain or leptomeningeal metastases thought to require immediate radiotherapy
- Presence of clinically significant third-space fluid collections (for example, ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to trial entry
- Yellow fever vaccination received within the 30 days previous to study entry
- Unable to interrupt aspirin or other NSAIDs (for pemetrexed arms of the trial)
- Unable or unwilling to take vitamin B12 and folic acid (for pemetrexed arms of the trial)
- A history of prior malignant tumour, unless the patient has been without evidence of disease for at least 3 years or the tumour was a non-melanoma skin tumour or early cervical cancer
- Pregnant or lactating women
- Inability to comply with protocol or trial procedures
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Platinum Arm
Cisplatin (IMP) / Pemetrexed (IMP)
|
|
|
实验性的:Non Platinum Arm
Paclitaxel (IMP) / Pemetrexed (IMP)
|
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Overall Survival
大体时间:Dec 2014
|
Dec 2014
|
次要结果测量
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Time to progression
大体时间:Dec 2014
|
Dec 2014
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Siow M. Lee, MD, PhD, FRCP、Cancer Research UK
研究记录日期
研究主要日期
学习开始
学习开始
初级完成 (实际的)
初级完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (估计)
首次发布
研究记录更新
最后更新发布 (估计)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.